Search

Aim: This study was conducted to evaluate the comfort level of patients receiving hemodialysis treatment. Material and Methods: This descriptive study was conducted with 262 patients receiving hemodialysis treatment between October and December 2018. Data were collected using "Patient Identification Form" and "Hemodialysis Comfort Scale. The data obtained from the study were analyzed by using SPSS (Statistical Package for Social Sciences) 25 program with number, percentage, independent samples t test and one way ANOVA. The Cronbach alpha coefficient of the scale used in the study was found to be 0.75. In the study, the significance level was accepted as p <0.05. Results: 59.5% of the patients were male, 30.5% were between the ages of 40-59 (x²=60.7±14.48, min:18-max: 92), 37% were retired, 70.2% of them had a moderate income level. It was found that 77.5% of the patients received 3 sessions of dialysis treatment per week and 65.6% of them had arteriovenous fistula. The mean score of subscale "overcoming" was 16.01±4.81, the mean score of subscale "relief" was 9.16±3.70 and the total scale mean score was 25.18±7.03. Conclusion: The comfort level of hemodialysis patients was found to be moderate. [ABSTRACT FROM AUTHOR]

Purpose:The aim of this study was to assess long-term efficacyy of tunnelled permanenThemodialysis catheters in end stage renal insufficiency patients and to detect complications which result in catheter dysfunction. Materials and Methods: We inserted 68 permanent catheters to 40 end stage renal insufficiency patients (28 female, 1 0 m ale; m ean a ge 5 8,2 years, r ange 2 0-80 years) under the guidance of ultrasonography and fluoroscopy in the study period of two years. We evaluated catheter related complications retrospectively and calculated survival of hemodialysis catheters. Results: We determined 58 long term complications (5.2 times in 1000 catheter days) which were; 28 cases of catheter thrombosis in 10 patients (2.5/1000 days), 14 cases of catheter related sepsis in 14 patients (1.25/1000 days), 3 cases of spontaneous extrusion of catheter in 3 patients (0.27/1000 days), 7 cases of bleeding at catheter insertion site in 6 patients (0.63/1000 days), 3 cases of inadequate blood flow in 3 patients (0.27/1000 days). The mean survival of catheters were 186 days, 133 days and 164 days in primary, secondary and in total respectively. Conclusion: The native arteriovenous (AV) fistulas are the best procedure of vascular access in chronic hemodialysis. Tunnelled permanenThemodialysis catheters prove to be a good alternative for patients who can not use AV fistulas. [ABSTRACT FROM AUTHOR]

Home hemodialysis (HD) has been supported by health authorities in many countries due to its nature of providing more freedom to the patients and the possibility to individualize the treatment. The treatment method is notable as a feasible dialysis option due to increase in life quality and improvement in the clinical findings of patients. However, pediatric home HD (HHD) is infrequently performed. In this study, we aimed to share our first year experience with HHD in a 15-year-old male patient. A 15-year-old male patient who had been receiving chronic peritoneal dialysis (CPD) for 13 years due to ESRD was transferred to chronic HD treatment due to treatment-resistant hypervolemia, hypertension, anemia and hyperphosphatemia associated with CPD failure. The education period was started with the consent of patient and his family and no problem was observed except short-term fear during the entry of a needle. Following the education period in the hospital, the treatment of the patient was continued at home. At the end of the first year of HHD treatment, increase in growth percentile and academic success, regression in the symptoms related to uremia, and also decrease in the use of medication and hospitalization were observed. Our patient felt better and had increased appetite, better growth scores and higher academic success, indicating that HHD could be a successful renal replacement treatment technique with its control of uremia-related symptoms and the decrease in medication needs of the patient. [ABSTRACT FROM AUTHOR]

Objective: This study aimed to investigate the effectiveness and tolerability of escitalopram in the treatment of major depressive disorder (MDD) in patients with end stage renal disease (ESRD). Method: One hundred and forty-five patients with ESRD were screened with Zung depression scale. The patients with Zung SDS measurements of 50% or above went through a psychiatric examination. Among the interviewed patients the ones, diagnosed with MDD based on DSM-IV and consented to participate in the study, were included. Those with any other comorbid axis I or II disorders and patients taking any psychotropic medications were excluded. The patients were randomly assigned to treatment with escitalopram or placebo. Clinical assessments were made by using Hamilton Rating Scale for Depression (HAM-D), Hamilton Rating Scale for Anxiety (HAM-A), and UKU Side Effects Rating Scale (UKU) at baseline and at 2nd , 4th and 8th weeks of treatment. Results: Seventy of 145 patients had SDS measurements of 50% or above. Of the 70 patients interviewed, 67 fullfilled the criteria for MDD according to DSM-IV. Five patients did not accept to participate, so 62 patients were included in the study. A total of 58 patients, 30 in the escitalopram group and 28 in the placebo group, completed the study. Patients taking escitalopram treatment showed a significantly greater reduction on HRSD scores compared to patients taking placebo. Likewise, side effect profile and severity with escitalopram were considered tolerable when compared with placebo. Conclusion: The results of this study suggest that escitalopram may be used effectively and with good tolerability in the treatment of MDD in patients with ESRD. [ABSTRACT FROM AUTHOR]